Skip to main content
SpringerLink
Log in

ICER publishes final report on disease-modifying therapies for MS

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Institute for Clinical and Economic Review. ICER's Final Report on Disease-Modifying Therapies for Multiple Sclerosis Finds Most Drugs are Over-Priced in Relation to Benefits for Patients; Highlights Need for Stakeholder Collaboration to Address System Issues. Internet Document : 6 Mar 2017. Available from: URL: https://icer-review.org/announcements/final-ms-report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER publishes final report on disease-modifying therapies for MS. PharmacoEcon Outcomes News 773, 2 (2017). https://doi.org/10.1007/s40274-017-3787-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3787-0

Search

Navigation